Pre-made Bertilimumab benchmark antibody (Whole mAb, anti-CCL11 therapeutic antibody, Anti-SCYA11 Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Anti-CCL11 therapeutic antibody (Pre-made Bertilimumab biosimilar, Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Bertilimumab is a human monoclonal antibody that binds to eotaxin-1, an important regulator of overall eosinophil function.
| Products Name (INN Index) | Pre-Made Bertilimumab Biosimilar, Whole Mab, Anti-Ccl11 Antibody: Anti-SCYA11 therapeutic antibody |
|---|---|
| INN Name | bertilimumab |
| Target | CCL11 |
| Format | Whole mAb |
| Derivation | Human |
| Species Reactivity | Human |
| CH1 Isotype | IgG4 – kappa |
| VD LC | IgG4 – kappa |
| Highest_Clin_Trial (Jan '20) | NA |
| Est. Status | NA |
| 100% SI Structure | NA |
| 99% SI Structure | NA |
| 95-98% SI Structure | NA |
| Year Proposed | NA |
| Year Recommended | NA |
| Companies | iCo?Therapeutics Inc. (Vancouver BC Canada) |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | NA |
| Development Tech | Cambridge Antibody Technology (CAT) human antibody phage display library |
| Previous Name | NA |
| Gm Offical Target Name | CCL11 |
| Package |
